Dementia and antihypertensive treatment by Birkenhäger, Willem H et al.
Dementia and antihypertensive treatment
Willem H. Birkenha¨gera, Franc¸oise Foretteb and Jan A. Staessenc
Purpose of review
We present an updated overview on the long-term effects of
hypertension on the occurrence of cognitive dysfunction and
overt degenerative or vascular dementia later in life. The
preventative effects of antihypertensive treatment in this regard
are examined, with a focus on placebo-controlled, double-blind,
randomized prospective trials.
Recent findings
The stereotypical straightforward linear relationship between
mid-life hypertension and dementia later in life can no longer be
considered strictly invariable. Successfully treated hypertensive
patients who are still at risk for clinical dementia late in life may
ultimately fare better in the presence of a slightly elevated rather
than low systolic blood pressure. The mechanisms underlying
this ‘J-curve’ phenomenon are currently being explored.
Recently completed prospective randomized antihypertensive
trials (Syst-Eur 2, PROGRESS and SCOPE) have yielded
variable results, and merit cautious interpretation.
Summary
The incidence and prevalence of dementia are increasing
exponentially worldwide, particularly in those older than 70
years. Because hypertension predisposes to dementia,
therapeutic blood pressure titration should be maintained over
the years, and intensified beyond 70 years in order to avoid
over-treatment in the latter period.
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Introduction
Roughly speaking, dementia is characterized by the
development of a range of intellectual and related
mental defects, such as progressive loss of memory,
increasing disorientation in space and time, loss of
autonomy, and emotional depersonalization. Hyperten-
sion has proven to be a major predisposing factor for the
development of both vascular and degenerative (Alzhei-
mer’s) dementias, either following stroke or through
more insidious microcerebrovascular processes, or both.
Such sequelae of hypertension and the protective
potential of antihypertensive (drug) treatment were
covered in a series of recent reviews [1–6]. However,
the accumulation of more recent epidemiological and
therapeutic findings linking blood pressure, cognitive
impairment and dementia creates the need for an
updated review.
Relative (ir)relevance of subtyping dementias
in relation to hypertension as a risk factor
Despite the extensive scientific knowledge of the
differential clinical and neuroanatomical hallmarks of
the two main dementia prototypes, namely Alzheimer’s
disease and vascular dementia, the importance of their
discriminating degenerative and vascular characteristics
has diminished in the face of integrated preventive
medicine. According to Hofman et al. [7], the two
subtypes share atherosclerosis as a major risk factor,
which is reflected by the use of hypertension as a
common denominator in several prospective, therapeutic
long-term trials (discussed below).
From the neuropathological perspective, an elaborate
and authoritative exploration, conducted under the
auspices of the Medical Research Council in the UK
[8], confirmed the existence of a common trait between
the substrates of the subtypes of dementia. Given this
considerable overlap between the two, it now seems
both appropriate and feasible to consider dementia as
one disease entity, at least for practical purposes at the
population level. Such a pragmatic approach (with all
due respect to the detailed literature inherited from the
past century that separates the two subtypes) would
greatly facilitate the design of future prospective trials on
the prevention of dementias.
Cognitive performance in relation to blood
pressure
According to a classic review of a dozen cross-sectional
studies of the correlation between blood pressure and
cognition [1], the results were far from uniform.
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Although differences in patient selection and methodol-
ogy may well have been responsible for the variance in
the observed relationships, it must be borne in mind that
the time scale of the natural history of hypertension per
se and the occurrence of its eventual sequela of cognitive
deterioration tend to differ widely. Hypertension is
mainly regarded as a mid-life phenomenon, whereas
dementia tends to occur in those older than 70 years.
Small wonder, then, that one must resort to longitudinal
observations in order to correlate the conditions.
In this regard, Elias et al. [9] broke new ground in the
Framingham cohort by examining cognitive function and
memory performance in hypertensive persons 12–14
years after recruitment, in relation to their initial blood
pressures. The majority of individuals (88%) had
remained untreated for hypertension in the interim.
After correction for demographical variables and cardio-
vascular risk factors other than high blood pressure, four
out of the eight implemented parameters of cognitive
performance were found to be negatively correlated with
initial systolic and diastolic blood pressures. In the
Honolulu–Asia Aging Study [10], a similarly negative
relationship was found between systolic blood pressure
at enrolment and risk for cognitive impairment after an
interval of 25 years.
In a meticulously conducted 15-year follow-up study,
Skoog et al. [11] examined blood pressure and dementia
in Gothenburg, Sweden. They analyzed the relation
between blood pressure and dementia starting with
nondemented hypertensive patients at age 70 years, and
then observing them again at age 70–75 years, 75–79
years and up to 85 years. Patients who developed
dementia in the final period of observation (i.e. age 79–
85 years) had higher systolic and diastolic blood
pressures at age 70 years than did those who did not
develop dementia. Remarkably, in the high-risk group,
blood pressure in the years just before the onset of
dementia tended to become lower than pressures in the
latter group. (This feature is discussed below.) In
another Swedish investigation, conducted by Kilander
et al. [12], 999 men were first examined at age 50 years
and followed up for 20 years. At age 70 years, cognitive
function was highest in the group with an initial diastolic
blood pressure below 70 mmHg and lowest in those with
a pressure greater than 105 mmHg. In the recently
reported Sydney Older Persons Study [13], 377 non-
demented persons aged 75 years and over were followed
up for 6 years. Of the 263 survivors after that period, 63
(16.7%) had developed dementia.
Hence, the trend identified from longitudinal studies
suggests that hypertension from mid-life onward tends to
predispose to the development of cognitive decline and
dementia during the course of the eighth decade of life.
It should be added that this course is modified in
hypertensive individuals who receive antihypertensive
treatment [14–16].
Evidence for a ‘J-curve’ relation between
blood pressure and dementia
In the previous section we referred to findings reported
by Skoog et al. [11], in their carefully conducted follow-
up study. Those investigators found that patients who
were prone to become demented, on the basis of past
hypertension, paradoxically exhibited lower blood pres-
sures in the years just preceding the development of
(mainly Alzheimer’s) dementia than did those who kept
well. White matter lesions on computed tomography also
seemed to predispose to such a decline in blood
pressure. Skoog [17] offered the hypothesis that failure
to maintain usual blood pressure at this stage might well
be an expression of Alzheimer-type lesions in prefrontal
autonomic centres, resulting in central dysregulation of
blood pressure. It may further be speculated that this
could give rise to subsequent orthostatic falls both in
blood pressure and in cerebral blood flow [18], which
would probably accelerate the process of cerebrocellular
damage.
In this regard, it may be worth mentioning the finding by
Bellelli et al. [19] that increased diurnal blood pressure
variability in elderly individuals (as an expression of
autonomic dysfunction) appeared to be related to a low
Mini-Mental State Examination score. Because that was
a small series, with antihypertensive drug treatment as a
potentially confounding factor, such data must be
confirmed on a larger scale in untreated older hyperten-
sive persons.
Irrespective of its putative mechanisms, this pheno-
menon may explain why occasional observations very
late in life [20] revealed that low systolic pressures
were an omen that preceded loss of cognition. In the
6-year Kungsholmen Project [16], it was a very low
diastolic pressure (565 versus 66–90 mmHg) that was
associated with an increased relative risk for dementia,
particularly in patients on antihypertensive treatment.
By contrast, high systolic blood pressures
(4180 mmHg) carried a similar relative risk, whereas
quite low systolic pressures (5140 mmHg) appeared to
be harmless in that study.
A recent small-scale, cross-sectional, but deeply probing
study conducted in Beer Sheva, Israel [21.] yielded
interesting findings in this regard. The team studied the
outcomes of eight cognitive tests, including Mini-Mental
State Examination and specific tests measuring memory,
concentration and visual retention, in 495 individuals
(age range 70–85 years, mean age 76.5 years) in relation
to repeatedly assessed blood pressure status. They
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categorized four blood pressure groups: normotensive
(mean blood pressure 122.6/72.6 mmHg; n = 136); nor-
malized hypertensive (mean blood pressure 126.8/
74.5 mmHg; n = 74); untreated hypertensive (mean
blood pressure 152.5/81 mmHg; n = 103); and treated,
uncontrolled hypertensive (mean blood pressure 158.7/
85.4 mmHg; n = 172). The results in the different
cognitive domains showed some variations. Neverthe-
less, the overall cognition scores suggest that in
individuals aged 70 years or over a blood pressure in
the order of 160/85 mmHg, particularly in those receiv-
ing antihypertensive treatment, confers optimal preser-
vation of cognitive functioning. Taking into account all
findings reported above one is bound to recognize the
existence of a J-curve appearing late in life, indicating a
measure of reversal in the originally positive relationship
between overt hypertension and dementia risk. As a
consequence, antihypertensive drug treatment should be
attentated when blood pressure levels tend to decline
below levels in the order of 160/85 mmHg.
Effects of antihypertensive drug regimes on
cognitive decline
Favourable effects of various antihypertensive drugs
have been reported in clinical, partly therapeutic, follow-
up studies on a post-hoc basis [15,22]. The effects of
treatment appeared to be favourable but the findings
failed to achieve statistical signficance, as summarized in
a previous review [2].
A recent study conducted in Indiana, USA [23] was
based on administrative data from 1900 older (age 465
years) nondemented hypertensive African-Americans,
with a follow-up period of 5 years. In this population
sample, 288 individuals (15.2%) developed cognitive
impairment. The use of antihypertensive medications
overall reduced the chances of developing dementia by
38% (odds ratio 0.62, 95% confidence intervals 0.48–
0.84). However, a corresponding analysis using reported
blood pressure measurements was inconclusive. More-
over, none of the seven antihypertensive drug categories
evaluated separately achieved significant reductions in
odds ratios.
These partially promising estimates of the ability of
antihypertensive drug treatment to preserve cognition in
older hypertensive individuals could not be confirmed
by findings in specifically studied subpopulations from
properly randomized, placebo-controlled, prospective
trials. None of the Systolic Hypertension in the Elderly
(SHEP) [24], the Medical Research Council [25] or the
Systolic Hypertension in Europe (Syst-Eur) [26] trialists
was able to detect significant cognitive benefits from the
use of active drugs (diuretics, b-blockers or a calcium
channel blocker) over their respective placebos, despite
significant net reductions in blood pressure (mainly
systolic). However, such a negative message need not
necessarily preclude a possible effect on the occurrence
of dementia as a predefined end-point.
Prevention of dementia by antihypertensive
regimes
Dementia was employed as a secondary end-point in
four major, long-term, placebo-controlled, randomized
trials conducted in older hypertensive patients.
In the SHEP trial substudy on 2034 individuals with
isolated systolic hypertension [24], the incidence of
dementia after 5 years was 1.9% in the placebo group
and 1.6% in the actively treated (primary drug chlortha-
lidone; not significant). According to a recent and more
detailed evaluation [27], a differential dropout and loss of
data from participants in the actively treated and placebo
groups may well have biased the analysis of cognitive
effects of active treatment, and might therefore have
obscured a significant protective action of the antihy-
pertensive medication.
After a median period of 2 years, The Syst-Eur trial [26]
demonstrated that active calcium channel blocker
(nitrendipine) based treatment reduced the incidence
of dementia by 50% compared with placebo (P = 0.05).
The number of incident cases was admittedly modest
(21 versus 11 cases). However, after the completion of
the double-blind phase of the trial, all patients, including
those originally randomized to placebo, were offered
further treatment with the active trial medication. This
unique modification of conventional trial design was
based on ethical and complementary considerations
regarding the safety of longer-term use of nitrendipine.
As far as was possible, monitoring during this secondary
open phase was continuous [28.]. As a result both the
median period of observation and the incidence of
dementia were doubled from 2 to 3.9 years and from 32
to 64 incident cases, respectively. The former placebo
group exhibited a somewhat higher average blood
pressure (by 7.0/3.2 mmHg) than did the group who
had received active treatment from the beginning of the
study. The latter group maintained a similar and even
more convincing reduction in incident dementia than in
the previous analysis (now –55%; P50.001). Figure 1
shows the overall course of events.
In the Perindopril Protection Against Recurrent Stroke
Study (PROGRESS) trial [29], the angiotensin-convert-
ing enzyme inhibitor perindopril failed to prevent
dementia. However, its combination with the diuretic
indapamide resulted in 23% reduction in the incidence
of dementia (P = 0.05). The Study on Cognition and
Prognosis in the Elderly (SCOPE) [30] tested the
protective effect of the angiotensin II receptor subtype
1 blocker candesartan against placebo. It should be
Dementia and antihypertensive treatment Birkenha¨ger et al. 227
noted that 80% of patients in the ‘placebo’ group were
actually being treated with a diuretic. No protective
effect of candesartan on dementia could be demon-
strated.
Taken together, these four heterogeneous trials yielded
an insignificant outcome with respect to the pooled odds
ratio (0.89, 95% confidence interval 0.75–1.04) [6]. This
inconclusive result was much dependent on the use of
drugs affecting the renin–angiotensin system. Exclusion
of the latter (perindopril without indapamide, candesar-
tan) leads to a more promising pooled odds ratio (0.75,
confidence intervals 0.60–0.94) [6].
Discussion
The central issue in the present review was to examine
the effects of currently available antihypertensive drugs
in terms of their potential additive benefit (i.e. on top of
their already established cardiovascular preventive ef-
fects) with regard to the generally predictable course of
cognitive decline and incidence of vascular and degen-
erative dementias in ageing hypertensive persons.
Before commenting on the overall findings of the trials
we feel compelled to raise a caveat regarding clinical
practice. According to recently extended findings, the
stereotypical straightforward relationship between blood
pressure elevation and cognitive malfunction appears to
take on a ‘J-shaped’ configuration very late in life. The
potential occurrence of such a ‘J-curve’ mandates careful
and regular monitoring of blood pressure during that
ultimate phase, particularly in those patients who are
responsive to treatment, in order to prevent relative
hypotension as a potential factor that worsens cognitive
failure.
Although arbitrary antihypertensive treatment efforts in
clinical practice suggested favourable effects on cogni-
tive decline in responsive hypertensive patients, such
statistically unsupported findings could not be con-
firmed in randomized, placebo-controlled trials. Never-
theless, to a varying extent overt dementia was found to
be preventable by combining the results of three (arms
of) trials (SHEP, PROGRESS and Syst-Eur), resulting
in a pooled odds ratio of 0.75 (95% confidence intervals
0.60–094; P = 0.01). It appeared that the use of the
dihydropyridine calcium channel blocker nitrendipine
as the primary drug in Syst-Eur was the most important
component in this overall result. In the latter trial,
including its open extension, the cumulative incidence
of dementia during a median course of 3.9 years was
reduced by 55% (Fig. 1). In our view, this cannot be
dismissed as a fortuitous finding, in view of the
probably fundamental role of cerebrocellular calcium
surfeit as a trigger of the neurotoxic cascade, which
ultimately leads to both degenerative and vascular
dementias.
The protective effects against the cardiovascular seque-
lae of hypertension in older hypertensives are, in
general, equal between the different drug classes, and
overall this leads to prolonged survival. This necessitates
a shift of attention toward preserving mental health in
the survivors.
Because of the loss of autonomy that occurs with
advanced age, the increasing size of the elderly
population worldwide will pose an enormous burden of
care, both regarding the direct (personal) environment
and society as a whole. The prevalence of (systolic)
hypertension in the ageing population is approximately
50%, and hence presumably this will constitute a major
proportion of those destined to become demented. This
indicates a new direction for research and development,
aimed at identifying and employing those antihyperten-
sive drug categories that carry the greastest potential for
delaying both degenerative and vascular dementias.
According to the present limited evidence available
from randomized therapeutic hypertension trials, the
category of dihydropyridine calcium channel blockers,
exemplified by nitrendipine, currently appears to be the
most promising in this regard. Admittedly this may still
be a fortuitous clinical finding. However, a range of basic
Figure 1. Incidence of dementias in the Syst-Eur, and the
subsequent Syst-Eur 2 trial, according to ‘intention to treat’ analysis
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After the completion of the double-blind phase (halfway through the
period of study), the original placebo group were switched to the same
active (basically trial bound) medication as the group randomly assigned
to active treatment from the start of the trial. The results are clearly in
favour of earlier (and more effective) active nitrendipine based treatment.
Adapted with permission from Forette et al. [28].
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research findings indicate that intracerebral neuronal
surfeit of calcium with ageing is likely to constitute a
major factor that initiates a cascade of neurotoxic effects
that ultimately lead to both degenerative and vascular
subtypes of dementia [31,32].
The major question is, where do we go from here?
According to Frishman [3], the prevention and manage-
ment of dementia are formidable public health
challenges that will continue well into the 21st cenury,
because the size of the older population will double in
the next 30 years. This is among the consequences of
reducing cardiovascular risk by virtue of antihyper-
tensive treatment as one of the most stringently
propagated factors. Because the current antihypertensive
drug categories in this respect appear to be similarly
effective, they all contribute to prolongation of survival
in a considerable proportion of elderly hypertensive
persons. Without concomitant efficacy for the prevention
of dementia, we are paradoxically left with a greater
burden of dementia in the population at large.
That gloomy perspective calls for a new and compelling
mission, in that the medical community should now
focus on the selection of those antihypertensive drugs
that specifically offer the best protection against
dementia. On the basis of the evaluation of randomized,
placebo-controlled trials conducted thus far, together
with considerations on a cerebrocellular level [31,32], the
most promising candidate drug type for a new,
comparative trial would be a dihydropyridine calcium
channel blocker with cerebral affinity as compared to
standard antihypertensive treatment with a diuretic
regimen.
Much to our regret, the pharmaceutical industry has
thus far remained unresponsive to such an iniative, for
undisclosed but imaginable marketing reasons. Clearly,
the huge ethical responsibility for this final touch,
which will hopefully lead to firm approach to prevention
worldwide, should now be appropriated by public
health authorities, including the World Health Organi-
zation.
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